Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
A Shigella species variant is causally linked to intractable functional constipation
Xin Chen, Tian-Tian Qiu, Ye Wang, Li-Yang Xu, Jie Sun, Zhi-Hui Jiang, Wei Zhao, Tao Tao, Yu-Wei Zhou, Li-Sha Wei, Ye-Qiong Li, Yan-Yan Zheng, Guo-Hua Zhou, Hua-Qun Chen, Jian Zhang, Xiao-Bo Feng, Fang-Yu Wang, Ning Li, Xue-Na Zhang, Jun Jiang, Min-Sheng Zhu
Xin Chen, Tian-Tian Qiu, Ye Wang, Li-Yang Xu, Jie Sun, Zhi-Hui Jiang, Wei Zhao, Tao Tao, Yu-Wei Zhou, Li-Sha Wei, Ye-Qiong Li, Yan-Yan Zheng, Guo-Hua Zhou, Hua-Qun Chen, Jian Zhang, Xiao-Bo Feng, Fang-Yu Wang, Ning Li, Xue-Na Zhang, Jun Jiang, Min-Sheng Zhu
View: Text | PDF
Research Article Gastroenterology

A Shigella species variant is causally linked to intractable functional constipation

  • Text
  • PDF
Abstract

Intractable functional constipation (IFC) is the most severe form of constipation, but its etiology has long been unknown. We hypothesized that IFC is caused by refractory infection by a pathogenic bacterium. Here, we isolated from patients with IFC a Shigella species — peristaltic contraction–inhibiting bacterium (PIB) — that significantly inhibited peristaltic contraction of the colon by production of docosapentenoic acid (DPA). PIB colonized mice for at least 6 months. Oral administration of PIB was sufficient to induce constipation, which was reversed by PIB-specific phages. A mutated PIB with reduced DPA was incapable of inhibiting colonic function and inducing constipation, suggesting that DPA produced by PIB was the key mediator of the genesis of constipation. PIBs were detected in stools of 56% (38 of 68) of the IFC patients, but not in those of non-IFC or healthy individuals (0 of 180). DPA levels in stools were elevated in 44.12% (30 of 68) of the IFC patients but none of the healthy volunteers (0 of 97). Our results suggest that Shigella sp. PIB may be the critical causative pathogen for IFC, and detection of fecal PIB plus DPA may be a reliable method for IFC diagnosis and classification.

Authors

Xin Chen, Tian-Tian Qiu, Ye Wang, Li-Yang Xu, Jie Sun, Zhi-Hui Jiang, Wei Zhao, Tao Tao, Yu-Wei Zhou, Li-Sha Wei, Ye-Qiong Li, Yan-Yan Zheng, Guo-Hua Zhou, Hua-Qun Chen, Jian Zhang, Xiao-Bo Feng, Fang-Yu Wang, Ning Li, Xue-Na Zhang, Jun Jiang, Min-Sheng Zhu

×

Figure 3

DPA is the active factor released from PIB.

Options: View larger image (or click on image) Download as PowerPoint
DPA is the active factor released from PIB.
(A and B) PIB culture supern...
(A and B) PIB culture supernatant was extracted with methanol/H2O/dichloromethane, and the substances in polar and nonpolar phases were subjected to contraction measurement. The contraction inhibition rate of the substances in the 2 phases was calculated (n = 3). (C) The substances in the dichloromethane phase were analyzed with HPLC with a C18 column. The arrow indicates the extra peak (red) of PIB medium in contrast to LB medium. The experiments were repeated 3 times. (D) The contraction-inhibiting activity for each eluted fraction of HPLC was measured. The fraction about 10.2 minutes after elution showed the highest activity. (E) The major resulting fragment ions are indicated in mass spectra of active fraction peaks and were extracted as DPA. The numbers indicate molecular weights of fragment ions. (F) cDPA had a substantial inhibitory effect on contraction. (G) Quantitation of the inhibitory effect of DPA (n = 4). (H) Colonic transit test with bead expulsion time in vehicle- and DPA-treated mice (n = 10). Data are presented as mean ± SD. **P < 0.01 (B, paired 2-tailed t test; H, unpaired 2-tailed t test).

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts